Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced its earnings results on Wednesday. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02, MarketWatch Earnings reports.
ZYNE opened at $11.96 on Friday. The firm has a market capitalization of $252.06 million, a price-to-earnings ratio of -4.58 and a beta of 5.62. Zynerba Pharmaceuticals has a 12-month low of $2.75 and a 12-month high of $13.33.
A number of research firms have issued reports on ZYNE. HC Wainwright reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Monday, March 18th. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, March 22nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $11.00 price objective on shares of Zynerba Pharmaceuticals in a report on Thursday, March 7th. ValuEngine upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, April 30th. Finally, Roth Capital began coverage on Zynerba Pharmaceuticals in a report on Tuesday, April 30th. They issued a “buy” rating and a $36.00 price objective for the company. Seven analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $18.52.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.
Read More: Intrinsic Value
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.